Hamster IgG

• Catalog Number: orb2652759
• Category: Proteins
• Description: Hamster IgG
• Tested applications: ELISA, IHC, SDS-PAGE, WB
• Isotype: IgG
• Concentration: 10.0 mg/mL
• Dilution range: ELISA: User Optimized, IHC: User Optimized, WB: User Optimized
• Form/Appearance: Lyophilized
• Purity: Hamster IgG whole molecule was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Hamster IgG whole molecule was assayed by immunoelectrophoresis resulted in a single precipitin arc against anti-GS Hamster IgG and anti-GS Hamster Serum.
• Conjugation: Unconjugated
• Hazard Information: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Biorbyt are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Biorbyt, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
• Source: Golden Syrian Hamster
• Biological Origin: Golden Syrian Hamster
• Storage: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Hamster IgG whole molecule is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
• Buffer/Preservatives: 0.01% (w/v) Sodium Azide. 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
• Alternative names: Hamster Immunoglobulin Gamma, Immunoglobulin G
• Note: For research use only
• Application notes: Hamster IgG whole molecule has been tested by SDS-Page and can be utilized as a control or standard reagent in Western Blotting and ELISA experiments. Reconstitution Buffer: Restore with deionized water (or equivalent). Reconstitution Volume: 1.0 mL
• Expiration Date: 6 months from date of receipt.

Anti-CD154–facilitated alloengraftment is multilineage. Twenty mice from 2 representative experiments shown in Figure 1 were phenotyped at 120 days after BMT for donor-host origin of CD4+ and CD8 + T cells, CD19 + B cells, and MAC-1 + myeloid cells. On the x-axis are shown the host and donor proportions of each of the lineages. ▪ indicates the proportion of each lineage of host origin; ▥, the proportion of each lineage that is of donor origin. On the y-axis is shown the percentage of PBLs of each lineage. Irrelevant hIgG–treated mice had no detectable donor chimerism and thus are composed entirely of host-type cells. Note that most CD4+ T cells, CD19 + B cells, and MAC-1 + myeloid cells in anti-CD154–treated mice are of donor origin. In contrast, most of the CD8 + T cells are of host origin.

Anti-CD40L mAb alone or in combination with (A) sirolimus or (B) CsA results in long-term multilineage engraftment.

Anti-PD-1 antibody plus radiation therapy (RT) cures mice with intracranial GL261-luc tumors. (A) Experimental timeline. (B) Luciferase imaging of 4 distinct mice per treatment arm before treatment (day 7) and after treatment (day 21), divided by treatment group. All images at same scale. All mice individually matched on days 7 and 21. (C) Kaplan-Meier survival curve. P 6 mice per arm.

Combination therapy with Cy/GVAX and PD-1 or PD-L1 blockade improves clinical outcomes in a PDA mouse model. Anti-PD-1, anti-PD-L1 or IgG (5 mg/kg IP) were administered IP twice weekly until death starting on day 3. (B) Kaplan-Meier survival curves of mice that were implanted with PDA cells and were treated with different combinations of Cy, GVAX and the αPD-1 antibody. The percentages of mice that remained disease free at day 90 following tumor implantation and therapy with (C) Cy, GVAX and/or αPD-1 or (D) Cy, GVAX and αPD-L1 are shown. All the p values were yielded by comparing GVAX and/or αPD-1/αPD-L1 treatment groups with IgG treated group. (E) Kaplan-Meier survival curves of mice that were implanted with Panc02 cells via hemispleen technique and treated with different combinations of Cy, GVAX and αPD-L1 antibody. Data are represented as results obtained from experiments with 8-10 mice per group that were repeated at least twice.

SDS-PAGE Results of Golden Syrian Hamster IgG Whole Molecule. Lane 1: Golden Syrian Hamster IgG Whole Molecule, Reduced [5.0 µg]. Lane 2: Opal Pre-Stained Molecular Weight Marker. Lane 3: Golden Syrian Hamster IgG Whole Molecule, Non-Reduced [5.0 µg]. 4-20% gel, Coomassie stained.